Practical Insights on Evolving Biomarkers for Precision Therapy in Lung Cancer

Get up to date on new and emerging biomarkers for personalized therapy in lung cancer in this interactive, case-based 1-hour live meeting developed by a medical oncologist and molecular pathologist, including review of the latest clinical data and expert guidance on patient cases. After the meeting, download the associated slideset for use in your clinic.

Register Now!


  • Current Status of Biomarker Testing in Lung Cancer
  • Newly Available and Emerging Biomarkers for Targeted Therapy in Lung Cancer
    • Evidence-Based Testing Strategies to Detect Appropriate Fusions and Mutations
    • Who Should Be Tested and Why
  • Predictive Biomarkers for Immune Checkpoint Inhibitor Therapy in Lung Cancer
  • Patient Case Discussions
    • Interpreting Biomarker Assay Results and How Results Should Affect Therapeutic Planning and/or Clinical Trial Enrollment
  • Practicalities of Biomarker Testing in Lung Cancer
    • Communication Among the Multidisciplinary Team


Date / Time
Event Details


Eric Konnick, MD, MS

Assistant Professor
Department of Laboratory Medicine
University of Washington
Seattle, Washington

Nathan Pennell, MD, PhD

Associate Professor
Cleveland Clinic Lung Cancer Medical Oncology Program
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Joshua Bauml, MD

Assistant Professor of Medicine 
Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Lyudmila A. Bazhenova, MD

Clinical Professor of Medicine 
Lung Cancer Unit Leader
Division of Hematology-Oncology
Department of Medicine
University of California, San Diego
San Diego, California

Thomas A. Hensing, MD

Clinical Associate Professor of Medicine
Department of Hematology and Oncology
University of Chicago
Chicago, Illinois
Co-Director, Thoracic Oncology Program
Kellogg Cancer Center
NorthShore University HealthSystem
Evanston, Illinois

Stephen Y. Liu, MD

Associate Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Sandip P. Patel, MD

Associate Professor
Division of Hematology and Medical Oncology
UC San Diego Moores Cancer Center
La Jolla, California

Zofia Piotrowska, MD, MHS

Harvard Medical School
Attending Physician
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Karen Reckamp, MD, MS

Professor of Medicine
, Division of Medical Oncology
Department of Medicine
Cedars Sinai
Los Angeles, California

Thomas Stinchcombe, MD

Vamsidhar Velcheti, MD

Jared Weiss, MD

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patient with lung cancer.

Target Audience
This program is intended for physicians, pathologists, and other healthcare providers who care for patients with lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply new and emerging predictive biomarkers to guide therapeutic decisions in patients with lung cancer
  • Summarize the available data and expert recommendations to determine which biomarkers should be tested in your patients with lung cancer
  • Evaluate the available next-generation sequencing and comprehensive genomic profiling diagnostic assays
  • Identify patients eligible to enroll on important ongoing clinical trials based on molecular testing of their tumor


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.